Latest news with #LINACs
Indian Express
a day ago
- Health
- Indian Express
Tata Memorial Centre, ICICI Bank launch construction of new Rs 550-crore block at Homi Bhabha Cancer Hospital in Visakhapatnam
Tata Memorial Centre (TMC), in collaboration with ICICI Bank, has commenced the construction of a new cancer care block at the Homi Bhabha Cancer Hospital and Research Centre (HBCHRC) in Visakhapatnam. The ICICI Foundation Block for Child and Blood Cancer, an eight-storey facility, is being funded through a Rs 550-crore commitment by the bank and is expected to be operational by 2027, subject to approvals. The new facility will add over 215 beds and is designed to treat 3,000 patients annually. It will focus on paediatric and hematolymphoid cancers, expanding the hospital's overall capacity and services, including bone marrow transplants and immunotherapy. The project is part of the bank's Rs 1,800-crore corporate social responsibility commitment to TMC, which also includes funding blocks in Navi Mumbai and New Chandigarh. Combined together, these blocks will cover 10.7 lakh sq ft and accommodate 555 beds and 19 Linear Accelerators or LINACs that are advanced devices for targeted cancer radiotherapy. 'This project, one of the largest in the eastern corridor for child and blood cancer, will serve patients from Andhra Pradesh and nearby eastern states, helping address the growing need for cancer treatment,' said ICICI Bank chairman Pradeep Kumar Sinha, who laid the foundation stone for the block in the presence of TMC director Dr Sudeep Gupta and other officials. The NK Rao Auditorium was also inaugurated at the same campus.
United News of India
24-05-2025
- Business
- United News of India
HCG posts Rs 5,851 million revenue in Q4 FY25
Bengaluru, May 24 (UNI) HealthCare Global Enterprises Ltd. (HCG), India's leading speciality healthcare provider focused on oncology and fertility, announced its unaudited financial results for the quarter and full year ended March 31, 2025. The company reported consolidated revenue of Rs 5,851 million for Q4 FY25, marking an 18% year-on-year growth from Rs 4,946 million in the corresponding quarter last year. For the full financial year 2025, HCG's revenue stood at Rs 22,228 million, reflecting a robust 16% growth over the previous year. EBITDA for Q4 FY25 was recorded at Rs 1,070 million, registering a 14% increase year-on-year, with margins at 18.3%. Profit After Tax (PAT) for the quarter was INR 74 million, down from Rs 213 million in Q4 FY24. Key operational highlights include a 3.5% rise in Average Revenue Per Operating Bed (ARPOB) to Rs 44,236, and an improvement in Average Occupancy Rate (AOR) to 67% from 63.2% in the previous year's quarter. The company also expanded its infrastructure by adding two Linear Accelerators (LINACs) at Vizag and Nagpur, and one PET CT facility in Africa. Dr BS Ajaikumar, Executive Chairman of HCG, said, "We have concluded another year of strong performance and meaningful progress. HCG continues to lead India's battle against cancer with a pan-India presence. We are investing in next-generation capabilities, including advanced molecular diagnostics and precision medicine. Our acquisition of the Orbitrap Astral Mass Spectrometer will significantly enhance our disease profiling and targeted therapy development." Raj Gore, CEO, added, "FY25 was a strong year operationally and financially. Excluding Milann centres, revenues grew by 17.4% to INR 21,651 million and Adjusted EBITDA increased 18.3% to Rs 3,913 million with margins of 18.1%. Our strategic acquisitions, including MG Hospital in Vizag, strengthen our regional presence and growth outlook. We remain confident about sustaining momentum into FY26.' HCG operates 22 comprehensive cancer centres across India and Africa and 7 fertility centres under the 'Milann' brand. UNI BDN RN
Yahoo
23-02-2025
- Business
- Yahoo
KKR Acquires Controlling Stake in Indian Healthcare Provider Healthcare Global Enterprises for $400 Million
KKR to be the largest and controlling shareholder MUMBAI, India, February 23, 2025--(BUSINESS WIRE)--KKR, a leading global investment firm, and Healthcare Global Enterprises (BSE: 539787; NSE: HCG; "HCG"), a leading healthcare organization in India, today announced the signing of definitive agreements with CVC, a leading global private markets manager, under which funds managed by KKR ("KKR") will become the largest shareholder in HCG and assume sole control of HCG's operations. Dr. BS Ajaikumar, Founder of HCG, will take on the role of Non-Executive Chairman and be focused on driving clinical, academic and research and development excellence. As part of the transaction, KKR will acquire up to 54% of equity in HCG from CVC Asia V at a purchase price of INR 445 per share. Pursuant to the Securities and Exchange Board of India's ("SEBI") Takeover Regulations, an open offer will be conducted by KKR to purchase additional equity shares in HCG from public shareholders. Upon completion of the transaction, KKR is expected to hold an equity stake of between 54-77%. Founded in 1989, HCG is one of India's largest oncology hospital chains. HCG operates 25 medical care centers across 19 cities with best-in-class infrastructure including 2,500 beds, nearly 100 operating theaters and 40 linear accelerator machines (LINACs). Akshay Tanna, Partner and Head of India Private Equity, KKR, said, "HCG is a pioneer in cancer care in India and has established itself as an important healthcare provider in the country for the past three decades. As healthcare continues to be a thematic focus for KKR in India, our investment in HCG will support the development of medical infrastructure and the delivery of critical oncology services and care to more patients in the country. We look forward to leveraging KKR's global healthcare expertise to strengthen HCG's offerings and working with Dr. BS Jaikumar to further enhance HCG's clinical excellence." Dr. BS Ajaikumar, Founder, HCG, said, "I want to thank CVC for their support through the years, helping the management to put HCG in the strong position it is in today. I am delighted to welcome KKR, with their investment and operational expertise in healthcare in India and globally, as a majority shareholder in HCG. Patient well-being and outcomes will always be a top priority for us at HCG, and in my new role as Non-Executive Chairman, I will focus on clinical aspects involving multi-disciplinary approach to cancer care, and research and development; and look forward to the journey of HCG where it continues to stay at the forefront of clinical excellence, research, and academics." Siddharth Patel, Managing Partner, CVC, said, "We are proud to have supported HCG's transformation at a critical juncture in time to build it into one of India's leading healthcare organizations and the delivery of high-quality care to many patients over the years." Amit Soni, Partner, CVC added, "Our partnership with Dr. Ajaikumar and the management team is a testimony to the ability to combine clinical and professional acumen to increase the reach of cancer care in India. We thank Dr. Ajai and the management for their unparalleled support and commitment to a common vision." KKR makes its investment from its Asia Fund IV. This transaction marks KKR's latest investment in India's healthcare space. Past investments in this sector have included Baby Memorial Hospital, a leading regional multi-specialty hospital chains in India; Healthium, a leading Indian medical devices company; Infinx, a tech-enabled healthcare revenue solutions provider; Max Healthcare, one of India's largest hospital networks; JB, a leading branded formulations pharmaceutical company in India and Gland Pharma, a leading Indian pure-play generic injectable pharmaceutical products company. The transaction is expected to close by the third quarter of 2025, subject to customary closing conditions and regulatory approvals. About HCG HealthCare Global Enterprises Ltd. (HCG), headquartered in Bengaluru, is one of the largest providers of cancer care in India. Through its network of 25 comprehensive cancer centers, HCG has brought advanced cancer care to the doorstep of millions of people. HCG's comprehensive cancer centers provide expertise and advanced technologies for the effective diagnosis and treatment of cancer under one roof. About KKR KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR's insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR's investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR's website at For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group's website at About CVC CVC is a leading global private markets manager with a network of 30 office locations throughout EMEA, the Americas, and Asia, with approximately €200 billion of assets under management. CVC has seven complementary strategies across private equity, secondaries, credit and infrastructure, for which CVC funds have secured commitments of approximately €249 billion from some of the world's leading pension funds and other institutional investors. Funds managed or advised by CVC's private equity strategy are invested in approximately 140 companies worldwide, which have combined annual sales of over €162 billion and employ over 580,000 people. For further information about CVC please visit: Follow us on LinkedIn. View source version on Contacts Media Inquiries For HCG Shipali S Poojaryshipali.p@ For KKR Wei Jun Ong+65 6922 For CVC Delna IraniAdfactors PR+91 22 6757 4444cvc@
